

J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

<http://www.uniquepharma.com>

StockExchange-NSE letters/MM:SA:451

February 11, 2014

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,


Sub : Unaudited Financial Results for the quarter/ nine months ended on
December 31, 2013

Enclosed please find unaudited financial results for the quarter/ nine months
ended on December 31, 2013. These financial results have been approved and
taken on record by the board of directors at its meeting held today.

We request you to take the above on record.

Thanking you,

Yours faithfully,
for J. B. Chemicals & Pharmaceuticals Limited


M. C. Mehta
Company Secretary - General Manager

Encl: As above

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

http://www.uniquepharma.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31/12/2013

Sl.No.	PART I - Particulars	Quarter ended			Nine Months		Year ended
		31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	31/03/2013
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	a. Net sales (Net of excise duty)	23,422.05	24,743.97	19,976.13	71,082.68	59,673.30	79,446.05
	b. Other Operating Income	530.12	574.68	453.10	1,710.93	1,454.61	2,196.20
	Total Income from Operations (Net) (a+b)	23,952.17	25,318.65	20,429.23	72,793.61	61,127.91	81,642.25
2	Expenses						
	a. Cost of materials consumed	7,871.24	7,834.52	6,509.73	23,531.11	19,979.60	26,190.38
	b. Purchases of stock-in-trade	1,682.55	1,584.92	1,947.23	5,506.61	5,055.79	7,155.17
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(332.92)	43.82	11.44	(496.58)	582.09	480.97
	d. Employees benefits expense	3,195.32	3,306.69	2,905.61	9,892.02	8,877.98	12,012.87
	e. Depreciation and amortization expense	600.00	750.00	625.00	2,100.00	1,839.00	2,439.58
	f. Exchange Fluctuation Transactional (Gain)/Loss	344.21	131.58	638.87	479.37	1,671.40	1,582.58
	g. Other Expenses	6,900.63	7,514.08	5,855.38	20,648.08	17,218.09	23,746.56
	Total Expenses	20,261.02	21,165.61	18,493.26	61,660.61	55,223.95	73,608.11
3	Profit from Operations before Other Income, Finance Cost and exceptional item (1-2)	3,691.14	4,153.04	1,935.97	11,133.00	5,903.96	8,034.14
4	Other Income (See Note 4)	2,084.49	680.86	700.89	2,916.87	2,339.30	2,596.07
5	Profit from Ordinary Activities before Finance Cost and exceptional item (3+4)	5,775.63	4,833.90	2,636.86	14,049.87	8,243.26	10,630.21
6	Finance Cost	189.72	189.87	187.97	526.47	407.76	524.18
7	Profit from Ordinary Activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	5,585.91	4,644.02	2,448.89	13,523.40	7,835.50	10,106.03
8	Exchange Fluctuation Translation Gain / (Loss)	991.62	(617.48)	674.86	(170.02)	655.64	668.44
9	Profit from Ordinary Activities after Exchange Fluctuation Translation Gain / (Loss) but before Exceptional item (7+-8)	6,577.53	4,026.54	3,123.75	13,353.38	8,491.14	10,774.47
10	Exceptional Item: Revision of purchase price in respect of Sale of Russia-CIS OTC Business Undertaking (See Note 3)	(6,450.00)	-	-	(6,450.00)	-	-
11	Profit before Tax (9-10)	127.53	4,026.54	3,123.75	6,903.38	8,491.14	10,774.47
12	Tax expenses (See Note 5)	774.99	712.27	936.35	2,204.02	1,972.52	2,280.62
13	Net Profit/(Loss) after Tax (11-12)	(647.46)	3,314.27	2,187.40	4,699.36	6,518.62	8,493.85
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,694.24	1,694.24	1,694.15	1,694.24	1,694.15	1,694.15
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	99,206.03
16	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	(0.76)	3.91	2.58	5.55	7.70	10.03
	(2) Diluted	(0.76)	3.91	2.58	5.55	7.69	10.03

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

http ://www.uniquepharma.com

Sl. No.	PART II - Particulars	Quarter ended			Nine Months		Year ended
		31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	31/03/2013
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	37,385,602	37,385,603	37,381,103	37,385,602	37,381,103	37,381,103
	- Percentage of shareholding	44.13	44.13	44.13	44.13	44.13	44.13
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	47,326,198	47,326,197	47,326,197	47,326,198	47,326,197	47,326,197
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.87	55.87	55.87	55.87	55.87	55.87

B INVESTOR COMPLAINTS

Particulars	3 Months ended 31/12/2013
Pending at the beginning of the quarter	1
Received during the quarter	11
Disposed of during the quarter	12
Remaining unresolved at the end of the quarter	NIL

NOTES

- The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on February 11, 2014.
- The statutory auditors have carried out limited review of the above financial results for the period ended on December 31, 2013.
- The exceptional item represents the amount which was no longer recoverable by the company out of the Escrow Account set up pursuant to the agreement dated July 14, 2011 with the purchaser of the company's Russia-CIS OTC Business undertaking, following commercial settlement of the disputes with the said purchaser. Instead of re-opening the audited accounts for the year 2011-12 to reflect the adjustment to the transaction consideration, the company has now decided to adjust the said amount as above in the current financial year and the results for the quarter ended December 2013.
- The other income includes write-back of the excess provision of Rs. 1764.48 lakhs made for expenses in relation to the sale of Russia-CIS OTC business undertaking by the company in July 2011.
- Tax expense is net of excess provision of tax in earlier year of Rs. 700 lakhs and MAT credit of earlier year of Rs.315.76 lakhs.
- The normal business operations for the quarter ended December 2013 show profit before tax and profit after tax of Rs. 4813.05 lakhs and Rs. 3022.30 lakhs respectively, while the year to date normal business operations show profit before tax and profit after tax of Rs. 11,588.90 lakhs and Rs. 8,369.12 lakhs respectively.
- The company is engaged in a single segment of activity viz. Pharmaceuticals.
- The previous quarter's/period's figures have been regrouped/re-stated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai

Date : February 11, 2014

J.B.Mody

Chairman & Managing Director